Sotera Health (NASDAQ:SHC) Stock Price Down 5.8% – What’s Next?

Sotera Health Company (NASDAQ:SHC) shares traded down 5.8% during trading on Tuesday. The company traded as low as $16.46 and last traded at $16.7060. 387,499 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 2,679,050 shares. The stock had previously closed at $17.74.

Sotera Health News Summary

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q3 results topped expectations: Sotera reported revenue of $324.9 million and adjusted earnings of $0.29 per share, above analyst estimates of $319.9 million and $0.27, respectively. Revenue grew 4.4% year over year, and shares rose 12.9% after the results. Sotera Health Company’s Q3 2026 sales top estimates, stock jumps 12.9%
• Positive Sentiment: Valuation and analyst coverage offer support: One analysis says SHC could be 28% below fair value following its earnings beat, while another report describes analysts as bullish on the stock. These views may help support the shares, though they are not company guidance. Sotera Health could be 28% below fair value Analysts are bullish on Sotera Health and Pfizer
• Neutral Sentiment: Q4 revenue guidance issued: Sotera provided fourth-quarter 2026 revenue guidance; the available headline does not give the forecast figures, so its implications for expectations are unclear. Sotera Health provides Q4 2026 revenue guidance
• Negative Sentiment: Medical-device market softness remains a concern: A Q3 review noted that weaker conditions in the medical-device market tempered otherwise stable growth, potentially limiting the pace of improvement. SHC Q3 deep dive: Medical-device market softness
• Negative Sentiment: JPMorgan turned more cautious: The bank cut its price target to $15 from $17 and maintained an underweight rating, signaling downside concerns. Barclays also lowered its target, to $20 from $22, but kept an overweight rating. JPMorgan lowers Sotera Health price target

Wall Street Analyst Weigh In

SHC has been the topic of several recent research reports. Barclays cut their price objective on shares of Sotera Health from $22.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 25th. JPMorgan Chase & Co. decreased their price objective on Sotera Health from $17.00 to $15.00 and set an “underweight” rating on the stock in a report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective on shares of Sotera Health in a report on Tuesday, September 8th. Finally, Citigroup lifted their target price on Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Sotera Health Stock Down 3.2%

The firm has a market cap of $4.53 billion, a P/E ratio of 26.45 and a beta of 1.94. The firm has a fifty day moving average of $18.29 and a 200-day moving average of $16.99. The company has a quick ratio of 2.55, a current ratio of 3.13 and a debt-to-equity ratio of 2.90.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. Sotera Health had a return on equity of 38.46% and a net margin of 14.11%. The firm had revenue of $324.89 million during the quarter, compared to analysts’ expectations of $319.86 million. During the same period in the previous year, the firm earned $0.26 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts anticipate that Sotera Health Company will post 0.87 earnings per share for the current year.

Insider Buying and Selling at Sotera Health

In related news, Chairman Michael Petras, Jr. sold 850,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the sale, the chairman owned 3,969,393 shares in the company, valued at $73,433,770.50. This represents a 17.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Rutz sold 150,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $18.84, for a total value of $2,826,000.00. Following the transaction, the insider owned 334,279 shares in the company, valued at $6,297,816.36. The trade was a 30.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 1,294,515 shares of company stock valued at $23,999,528. 15.36% of the stock is owned by corporate insiders.

Institutional Trading of Sotera Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Sotera Health during the third quarter valued at $29,000. Meeder Asset Management Inc. bought a new position in shares of Sotera Health in the second quarter valued at approximately $37,000. Root Financial Partners LLC grew its position in shares of Sotera Health by 217.5% during the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after purchasing an additional 1,455 shares in the last quarter. Provenance Wealth Advisors LLC bought a new position in Sotera Health in the 3rd quarter worth about $42,000. Finally, Nykredit A S purchased a new position in Sotera Health in the 2nd quarter worth approximately $50,000. 91.03% of the stock is owned by institutional investors.

About Sotera Health

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.